Top Abstract Purchase Related
Home
>
Node
>
Subnode

Evaluation of a new anti-cancer drug regimen for endometrial cancer

Fushiki, H.; Hidaka, T.; Hori, S.; Fujimura, M.; Yamakawa, Y.; Izumi, R.

Gan to Kagaku Ryoho. Cancer and ChemoTherapy 25(1): 75-78

1998

ISSN/ISBN: 0385-0684
PMID: 9464332
Document Number: 493914
The purpose of this study was to describe a new anti-cancer drug regimen for endometrial cancer. The cytotoxicities of some anti-cancer drugs regimens against human endometrial cancer xenografted into nude mice (TEI, TET, TEU, TEN) have been studied. The activities of ADM, CDDP, CPM, CPT-11, TXL, CDDP + ADM, CDDP + CPM, CDDP + CPT-11, CDDP + TXL, CPT-11 + TXL were evaluated in comparison with a control group using saline. Three mice were used for each group, and when xenografted tumor reached 6 mm of its diameter, 1/5 LD50 of these drugs was administered into the periotoneal cavity mice once a week for three weeks. The effective regimens were CPT-11 + TXL, CDDP + CPT-11, CDDP + CPM, CDDP + TXL for the endometrial cancer. It is suggested that these new drugs regimens should be tested in clinical studies.

Document emailed within 1 workday
Secure & encrypted payments

Gil-Ad, I.; Zolokov, A.; Lomnitski, L.; Taler, M.; Bar, M.; Luria, D.; Ram, E.; Weizman, A. 2008: Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice International Journal of Oncology 33(2): 277-286
Guleria, K.; Agarwal, N.; Mishra, K.; Gulati, R.; Mehendiratta, A. 2004: Evaluation of endometrial steroid receptors and cell mitotic activity in women using copper intrauterine device: Can Cu-T prevent endometrial cancer? Journal of Obstetrics and Gynaecology Research 30(3): 181-187
Felix, A.S.; Gaudet, M.M.; La Vecchia, C.; Nagle, C.M.; Shu, X.O.; Weiderpass, E.; Adami, H.O.; Beresford, S.; Bernstein, L.; Chen, C.; Cook, L.S.; De Vivo, I.; Doherty, J.A.; Friedenreich, C.M.; Gapstur, S.M.; Hill, D.; Horn-Ross, P.L.; Lacey, J.V.; Levi, F.; Liang, X.; Lu, L.; Magliocco, A.; McCann, S.E.; Negri, E.; Olson, S.H.; Palmer, J.R.; Patel, A.V.; Petruzella, S.; Prescott, J.; Risch, H.A.; Rosenberg, L.; Sherman, M.E.; Spurdle, A.B.; Webb, P.M.; Wise, L.A.; Xiang, Y.-B.; Xu, W.; Yang, H.P.; Yu, H.; Zeleniuch-Jacquotte, A.; Brinton, L.A. 2015: Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium International Journal of Cancer 136(5): E410-E422
Neri, F.; Maggino, T. 2009: Surveillance of endometrial pathologies, especially for endometrial cancer, of breast cancer patients under tamoxifen treatment European Journal of Gynaecological Oncology 30(4): 357-360
Zwiebel, J. 2016: The effect on drug development of the National Cancer Institute's Cancer Therapy Evaluation Program Clinical Advances in Hematology and Oncology: H&o 14(3): 157-159
Senzer, N.N.; Terrell, W.; Pratt, C.B. 1978: Evaluation of a chemotherapeutic regimen for primary liver cancer in children Cancer Treatment Reports 62(9): 1403-1404
Beggs, W.H. 1993: Anti-Candida activity of the anti-cancer drug tamoxifen Research Communications in Chemical Pathology and Pharmacology 80(1): 125-128
Bokhman, I.V.; Chepik, O.F.; Volkova, A.T.; Vishnevskiĭ, A.S. 1982: Is a cure possible for primary state-i endometrial cancer using drug therapy? Voprosy Onkologii 28(3): 34-42
Hegazy, S.K.; El-Azab, G.A.; Zakaria, F.; Mostafa, M.F.; El-Ghoneimy, R.A. 2022: Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer Life Sciences 299: 120536
Campbell, K.; Nuss, R.C.; Benrubi, G.I. 1988: An evaluation of the clinical staging of endometrial cancer Journal of Reproductive Medicine 33(1): 8-10
Chen, L.M.; McGonigle, K.F.; Berek, J.S. 1999: Endometrial cancer: recent developments in evaluation and treatment Oncology 13(12): 1665-1670; Discussion: 1675-1678; 1681-1682
Gao, M.; Gao, Y.-n.; Yan, X.; Zheng, H.; Jiang, G.-q.; Wang, W.; Zhang, N.-y. 2013: Evaluation of complications of different operation modes in endometrial cancer Zhonghua Zhong Liu Za Zhi 35(12): 932-935
Caceres, G.; Dauphinee, M.J.; Eisele, L.E.; MacColl, R.; Mizejewski, G.J. 2002: Anti-prostate cancer and anti-breast cancer activities of two peptides derived from alpha-fetoprotein Anticancer Research 22(5): 2817-2820
Molina, G.; Dell'Elce, C.; Libanori, E.; Preziuso, F.; Trompeo, P. 1996: Transvaginal echographic evaluation of myometrial invasion in patients with endometrial cancer Minerva Ginecologica 48(6): 239-242
Buthiau, D.; Antoine, E.; Gozy, M.; Khayat, D.; Dargent, D. 1996: Endometrial cancer: progress in the evaluation of locoregional extension by imaging techniques Contraception Fertilite Sexualite 24(10): 757-761
Yoshida, M.; Suzuki, S.; Enokida, T.; Ishiki, H.; Ichida, Y.; Saitoh, S.; Endo, K.; Izumi, K.; Tahara, M. 2014: Evaluation of aprepitant as a prophylactic antiemetic in the Cisplatin split regimen combined with radiation for patients with head and neck cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(9): 1103-1106
Pete, I.; Godény, M.; Tóth, E.; Radó, J.; Pete, B.; Pulay, T. 2003: Prediction of cervical infiltration in Stage Ii endometrial cancer by different preoperative evaluation techniques (D&C, US, CT, MRI) European Journal of Gynaecological Oncology 24(6): 517-522
Kumar, D.; Ahuja, V.; Dhar, A.; Sharma, M.P. 2001: Randomized trial of a quadruple-drug regimen and a triple-drug regimen for eradication of Helicobacter pylori: long-term follow-up study Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology 20(5): 191-194
Michaelis, M.; Doerr, H.W.; Cinatl, J. 2007: Valproic acid as anti-cancer drug Current Pharmaceutical Design 13(33): 3378-3393
Mazurek, A.; Kuc, P.; Terlikowski, S.; Laudanski, T. 2006: Evaluation of tumor angiogenesis and thymidine phosphorylase tissue expression in patients with endometrial cancer Neoplasma 53(3): 242-246